A Phase I, Two Part Study Exploring the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effect of Ascending Doses of BL-8040 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2016
At a glance
- Drugs BL 8040 (Primary)
- Indications Stem cell mobilisation
- Focus Adverse reactions
- Sponsors BioLineRx
- 19 Apr 2016 Results published in BioLineRx media release.
- 30 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 15 Jun 2015 Results of this study were presented at the 20th Annual Congress of the European Hematology Association as per a BioLineRx media release.